<DOC>
	<DOCNO>NCT01962545</DOCNO>
	<brief_summary>The purpose study evaluate non-inferiority oral anticoagulant ( OAC ) monotherapy OAC plus single antiplatelet therapy ( APT ) patient atrial fibrillation ( AF ) prior ( &gt; 12 month ) coronary stenting .</brief_summary>
	<brief_title>Optimizing Antithrombotic Care Patients With AtriaL fibrillatiON Coronary stEnt ( OAC-ALONE ) Study</brief_title>
	<detailed_description>It report 5-10 % patient undergo percutaneous coronary intervention ( PCI ) concomitant AF . Most patient indication OAC therapy prevent stroke systemic thromboembolism , also APT prevent ischemic cardiac event , particularly myocardial infarction ( MI ) due stent thrombosis ( ST ) . However , combine use OAC APT associate increase risk major bleeding . Thus , need balance risk stroke systemic thromboembolism coronary event risk bleed complication . The AF guideline European Society Cardiology ( ESC ) publish 2010 recommend vitamin-K antagonist ( VKA ) monotherapy life-long antithrombotic therapy 12 month combine use VKA plus APT AF patient undergo coronary stenting . Single APT either aspirin clopidogrel commonly use APT regimen non-AF patient beyond 1-year PCI-stenting . No APT coverage coronary stenting report associate increased risk ST . It yet thoroughly clarify whether VKA monotherapy equally effective single APT prevention ST , although several RCTs show VKA effective aspirin secondary prevention ischemic cardiac event post-MI patient mostly untreated coronary stent , recent observational study suggest safety VKA monotherapy beyond 1-year PCI-stenting . Nevertheless , RCTs focus safety VKA monotherapy AF patient chronic phase PCI-stenting . Also , phase-3 RCTs compare warfarin non-VKA OAC ( NOAC ) prevention stroke systemic embolism AF patient show significant difference incidence MI follow-up , consensus document ESC publish 2014 recommend OAC monotherapy either VKA NOAC life-long antithrombotic therapy beyond 1-year coronary stenting AF patient . However , RCTs observational study demonstrate safety NOAC alone beyond 1-year PCI-stenting . Accordingly , plan prospective randomized control open label trial compare OAC alone versus OAC plus single APT AF patient beyond 1-year PCI-stenting . AF patient receive OAC either warfarin NOAC combination single APT either aspirin clopidogrel , underwent PCI-stenting 12 month ago , eligible study . Patients randomly assign OAC alone ( intervention arm , discontinue single APT ) OAC plus single APT ( control arm , change antithrombotic therapy ) . The patient enrollment period approximately 3 year follow-up duration least 1 year . Therefore , anticipate mean follow-up duration approximately 2.5-year .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Patients document history AF underwent PCI stenting &gt; 12 month enrollment . 2 . Patients treat OAC ( warfarin NOAC ) antiplatelet drug ( aspirin clopidogrel ) , antiplatelet drug include ticlopidine , prasugrel , ticagrelor , cilostazol . 3 . In patient treated warfarin , INR value enrollment = &gt; 1.6 , agreement dose adjustment warfarin target INR range 2.03.0 &lt; 70 year 1.62.6 = &gt; 70 year , recommend Japanese guideline , necessary enrollment . 4 . Patients 20 year old . 5 . Patients write informed consent . 1 . Patients underwent PCI include balloon angioplasty alone within past 12 month . 2 . Patients OAC schedule discontinue followup period . 3 . Patients past history ST. 4 . Patients plan coronary revascularization . 5 . Patients plan cardiovascular noncardiovascular surgery . 6 . Patients expectation survival less one year .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Stent</keyword>
	<keyword>Anticoagulant therapy</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Warfarin</keyword>
	<keyword>NOAC</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>